Company Filing History:
Years Active: 2013
Title: Tzu-Yang Weng: Innovator in RNAi Technology
Introduction
Tzu-Yang Weng is a prominent inventor based in Tainan, Taiwan. He has made significant contributions to the field of RNA interference (RNAi) technology, particularly in the context of cancer treatment and immune response activation. His innovative work has led to the development of a unique RNAi compound that targets thrombospondin-1.
Latest Patents
Tzu-Yang Weng holds a patent for an RNAi compound targeted to thrombospondin-1 and its applications. This invention relates to an RNAi compound and an expression plasmid designed to inhibit the expression of thrombospondin-1. The patent outlines a pharmaceutical composition that includes the RNAi compound, which can effectively reduce thrombospondin-1 expression to activate immune responses. Furthermore, the invention demonstrates that the RNAi compound can delay tumor progression, showcasing its potential in cancer therapy.
Career Highlights
Tzu-Yang Weng is affiliated with National Cheng Kung University, where he continues to advance research in RNAi technology. His work has garnered attention for its innovative approach to addressing critical health challenges, particularly in oncology.
Collaborations
Tzu-Yang Weng has collaborated with notable colleagues, including Ming-Derg Lai and Shih-Shien Huang. These partnerships have contributed to the advancement of research in the field and have fostered a collaborative environment for innovation.
Conclusion
Tzu-Yang Weng's contributions to RNAi technology exemplify the impact of innovative research on healthcare. His patent for an RNAi compound targeting thrombospondin-1 highlights the potential for new therapeutic strategies in cancer treatment.